Gilead to acquire Kite for $11.9 billion

Gilead Sciences Inc has made a dramatic entry to the field of regenerative medicine with an agreed bid for Kite Pharma Inc which has a portfolio of engineered cell therapies, the most advanced of which is under review in both the US and the EU.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States